The Food and Drug Administration (FDA) approved eribulin mesylate (Halaven®) on January 28 for some patients with liposarcoma. The approval is for patients whose cancers are advanced (metastatic) or cannot be removed by surgery (unresectable) and are no longer responding to anthracycline-based chemotherapy.
"The approval offers a therapeutic option for a disease with minimal treatment options," said Chris Heery, M.D., director of the Clinical Trials Group in NCI's Center for Cancer Research.
from Cancer via ola Kala on Inoreader http://ift.tt/1KJwZDh
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου